To the Editor We were delighted to read the editorial by Divito¹ and find growing attention to severe cutaneous adverse [drug] reactions (SCARs). In the last 2 decades, endeavors by international multidisciplinary scientific networks have greatly advanced our understanding of the pathogenesis of SCARs. An important innovation has been translating the discoveries in SCAR pharmacogenetics into preventive genetic screening of at-risk populations. Notable HLA antigen drug associations for SCARs include HLA-B*57:01 (abacavir-induced Stevens-Johnson syndrome/toxic epidermal necrolysis [SJS/TEN] and drug reaction eosinophilia and systemic symptoms [DRESS]), HLA-B*15:02 (carbamazepine-induced SJS/TEN), HLA-B*58:01 (allopurinol-induced SJS/TEN and DRESS), and HLA-B*13:01 (dapsone-induced DRESS). Screening programs have been established by governments across Asia, including Taiwan, Hong Kong, Singapore, and Thailand.